In a CML mouse model, Scott et al. demonstrated that EZH2 was overexpressed in LSCs and that its dysregulation was responsible for TKI resistance and LSCs’ protection [87]. Here, EZH2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.